Our Technology
Novel Mucosal Adsorption Drug Delivery Platform — reimagining how drugs are absorbed.
Oral Bioavailability Crisis
Approximately 40% of marketed drugs and up to 90% of drugs in development pipelines suffer from poor aqueous solubility, leading to low oral bioavailability, variable absorption, and suboptimal therapeutic outcomes.
Traditional oral formulations face first-pass metabolism, gastric degradation, and limited absorption windows — resulting in higher doses, increased side effects, and poor patient compliance.
Polymer Bridge & Mucosal Adsorption
Our proprietary platform utilizes a novel polymer bridge mechanism that enables drug molecules to adhere directly to mucosal tissue — bypassing first-pass metabolism and dramatically improving bioavailability.
The technology creates a sustained-release mucoadhesive matrix that prolongs drug residence time at the absorption site, enabling lower doses with higher efficacy and reduced side effects.
Key Benefits
-
Improved aqueous solubility for poorly soluble drugs
-
Enhanced mucosal residence time for superior absorption
-
Applicable across multiple drug classes and indications
-
Lower dose requirements with improved bioavailability
-
Platform technology enabling rapid formulation development
Global Licensing & Tech Transfer
Our platform is available for global licensing and technology transfer partnerships. We work with pharmaceutical companies worldwide to apply our mucosal adsorption technology to their existing and development-stage drug candidates, accelerating time-to-market and improving product differentiation.